Pharmaceuticals News and Research

RSS

Rexahn closes sale of $10 million of securities in registered direct offering

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced the closing of a previously announced sale of an aggregate of $10 million of securities in a registered direct offering. Rexahn received net proceeds of approximately $9.28 million after deducting placement agent fees and other offering expenses.

1 Jul 2010

Cubist commences enrollment in Phase 2 study of CXA-201 for complicated intra-abdominal infections

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced the enrollment of the first patient in a Phase 2 study with CXA-201. This multicenter, double-blind, randomized, study will compare the safety and efficacy of intravenous CXA-201 with an active comparator in patients with complicated intra-abdominal Infections (cIAI). This international study is expected to enroll 120 patients.

1 Jul 2010

Neuralstem announces completion of $10 million registered direct offering

Neuralstem, Inc. (NYSE Amex: CUR) announced that it has completed its previously announced registered direct offering of $10 million of units to institutional investors. The units were priced at $2.80 and consisted of: (i) one share of common stock, and (ii) 3/4 common stock purchase warrant. The warrants have an exercise price of $3.25 and a term of three years. Net proceeds from this offering, after deducting placement agent fees and other offering expenses, total approximately $9.2 million. All of the securities were offered pursuant to an effective shelf registration statement.

1 Jul 2010

Prasco commences shipments of generic prescription ZEGERID Capsules

Santarus, Inc., a specialty biopharmaceutical company, today announced that pursuant to its distribution and supply agreement with Prasco, LLC, Prasco is commencing shipments of an authorized generic of prescription ZEGERID® (omeprazole/ sodium bicarbonate) Capsules in 20 mg and 40 mg dosage strengths in the U.S. under the Prasco label. ZEGERID is an immediate-release proton pump inhibitor (PPI) approved as a prescription product in the U.S. for the treatment of certain upper gastrointestinal diseases and disorders.

1 Jul 2010

Fero Industries closes acquisition of rights related to production, marketing and distribution of Sucanon

Fero Industries, Inc. is pleased to announce that it has closed the acquisition of certain intellectual property and other associated rights related to the production, marketing, and distribution of Sucanon, a treatment for Type II diabetes.

1 Jul 2010

SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released information regarding a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection in elderly patients with acute myeloid leukemia (AML). The comparator in this trial was low-dose cytarabine, a chemotherapy agent, or supportive care.

30 Jun 2010

Vicept completes $16 million Series A financing

Vicept™ Therapeutics Inc., a privately held specialty biopharmaceutical company dedicated to developing the first effective topically applied therapy for erythema (facial redness) of rosacea, announced that it has secured $10 million to complete a total $16 million Series A financing. The Series A was led by Vivo Ventures, Sofinnova Ventures and Fidelity Biosciences.

30 Jun 2010

Calistoga Pharmaceuticals closes $40 million Series C financing

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced it has closed a $40 million Series C financing. The financing was led by Quogue Capital, LLC along with existing investors Alta Partners, Amgen Ventures, Frazier Healthcare and Three Arch Partners and new investor Latterell Venture Partners.

30 Jun 2010

Investment report on BioCryst Pharmaceuticals

MicroStockProfit.com announces an investment report featuring BioCryst Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.

30 Jun 2010

BioSante reports positive results from Phase II study of Pill-Plus "triple hormone" oral contraceptive

BioSante Pharmaceuticals, Inc. announced today positive results in a Phase II study of the Pill-Plus "triple hormone" oral contraceptive (OC). Results showed an increase in the frequency of sexual activity (p< 0.05) and reduced frequency of rejection of initiation of sexual activity by partner (p< 0.05).

30 Jun 2010

Raptor partners with Uni Pharma to commercialize Convivia in Taiwan

Raptor Pharmaceutical Corp., announced that it has entered into an exclusive agreement with Uni Pharma Co., Ltd. to commercialize Convivia™, Raptor's proprietary oral formulation of 4-methylpyrazole, in Taiwan.

30 Jun 2010

New chemical method for drug design, agrichemicals

University of Delaware scientist Donald Watson is part of a research team that has discovered an easier method for incorporating fluorine into organic molecules, giving chemists an important new tool in developing materials ranging from new medicines to agricultural chemicals.

30 Jun 2010

ICON Central Laboratories partners with FMD to open new laboratory facility in China

ICON Central Laboratories - a division of ICON plc,, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries - today announced the opening of a new laboratory facility in Tianjin, China, in partnership with Fountain Medical Development Ltd (FMD). It is the third ICON laboratory in the Asia-Pacific region.

30 Jun 2010

NORD urges FDA to reduce regulatory uncertainty in developing medicines for rare disorders

Noting that only about 200 of the nearly 7,000 diseases classified as rare currently have treatments, the National Organization for Rare Disorders (NORD) today called for a Food and Drug Administration (FDA) statement of policy on regulation of therapies for rare disorders.

30 Jun 2010

Medivir's rights issue changes number of shares and votes

The number of shares and the number of votes in Medivir have changed as a result of the rights issue carried out by the company as well as the exercise of employee stock options.

30 Jun 2010

Cubist Phase 2 trial for efficacy of CXA-101 in complicated urinary tract infections meets objectives

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that the recently-completed Phase 2 study of CXA-101, a novel cephalosporin, compared to ceftazidime for the treatment of complicated urinary tract infections (cUTI) in adults met its study objectives.

30 Jun 2010

Aeolus AEOL 10150 study confirms ability to rescue skin from deleterious effects of CEES

Aeolus Pharmaceuticals, Inc. reported that researchers from National Jewish Health and the University of Colorado Anschutz Medical Campus have completed studies demonstrating that AEOL 10150 provides statistically significant protection of the skin in the 2-chloroethyl-ethylsulfide (CEES; half mustard) model of mustard gas exposure in mice and in a human cell culture model.

30 Jun 2010

Sirnaomics receives NIH SBIR grants to advance siRNA therapeutics for critical human diseases

Sirnaomics, Inc. announced today that the company has received two SBIR (Small Business Innovation Research) grants from National Cancer Institute (NCI) and National Institute of Allergy and Infectious Diseases (NIAID), of National Institute of Health (NIH). Sirnaomics, Inc., a biopharmaceutical company founded in early 2007, is dedicated to developing RNA interference (RNAi) therapeutics for treatment of critical human diseases.

30 Jun 2010

Amylin presents improved indices of beta-cell function after three years of BYETTA(R) therapy

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a study comparing the effect of long-term treatment with either BYETTA® (exenatide) injection or Lantus® (insulin glargine) on overall beta-cell function. (Beta cells are cells in the pancreas that produce insulin.) Three years of BYETTA therapy improved indices of beta-cell function assessed four weeks after discontinuing therapy. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Fla.

30 Jun 2010

FDA grants approval for first generic version of Effexor XR antidepressant capsules

On June 28, the U.S. Food and Drug Administration approved the first generic version of Effexor XR capsules (venlafaxine hydrochloride) to treat major depressive disorder.

30 Jun 2010

Pharmaceuticals News and Research

Rexahn closes sale of $10 million of securities in registered direct offering

Cubist commences enrollment in Phase 2 study of CXA-201 for complicated intra-abdominal infections

Neuralstem announces completion of $10 million registered direct offering

Prasco commences shipments of generic prescription ZEGERID Capsules

Fero Industries closes acquisition of rights related to production, marketing and distribution of Sucanon

SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication

Vicept completes $16 million Series A financing

Calistoga Pharmaceuticals closes $40 million Series C financing

Investment report on BioCryst Pharmaceuticals

BioSante reports positive results from Phase II study of Pill-Plus "triple hormone" oral contraceptive

Raptor partners with Uni Pharma to commercialize Convivia in Taiwan

New chemical method for drug design, agrichemicals

ICON Central Laboratories partners with FMD to open new laboratory facility in China

NORD urges FDA to reduce regulatory uncertainty in developing medicines for rare disorders

Medivir's rights issue changes number of shares and votes

Cubist Phase 2 trial for efficacy of CXA-101 in complicated urinary tract infections meets objectives

Aeolus AEOL 10150 study confirms ability to rescue skin from deleterious effects of CEES

Sirnaomics receives NIH SBIR grants to advance siRNA therapeutics for critical human diseases

Amylin presents improved indices of beta-cell function after three years of BYETTA(R) therapy

FDA grants approval for first generic version of Effexor XR antidepressant capsules

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence